Literature DB >> 16930694

Is "leukemia" an appropriate label for all patients who meet the diagnostic criteria of chronic lymphocytic leukemia?

A Victor Hoffbrand1, Terry J Hamblin.   

Abstract

Chronic lymphocytic leukemia is a frightening diagnosis which we believe is mistakenly applied to patients who will live their whole lives without symptoms referable to this diagnosis and never require treatment for it. Changes in the threshold of lymphocytosis required for the diagnosis have led to many more people being inappropriately diagnosed. In addition, modern prognostic factors have enabled us to predict with a fair degree of accuracy which patients presenting with a lymphocytosis will have a benign course and which will require treatment. We propose a new category of benign monoclonal lymphocytosis be recognized, better to reflect reality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930694     DOI: 10.1016/j.leukres.2006.07.006

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group.

Authors:  Stefano Molica; Francesca R Mauro; Diana Giannarelli; Francesco Lauria; Agostino Cortelezzi; Maura Brugiatelli; Vincenzo Liso; Antonio Cuneo; Robin Foà
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 2.  Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management.

Authors:  T D Shanafelt; P Ghia; M C Lanasa; O Landgren; A C Rawstron
Journal:  Leukemia       Date:  2010-01-21       Impact factor: 11.528

3.  A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL).

Authors:  Stefano Molica; Diana Giannarelli; Luciano Levato; Rosanna Mirabelli; Massimo Gentile; Mirella Lentini; Fortunato Morabito
Journal:  Int J Hematol       Date:  2014-07-27       Impact factor: 2.490

4.  IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Authors:  D Rizzo; J Chauzeix; F Trimoreau; J B Woillard; F Genevieve; A Bouvier; J Labrousse; C Poli; E Guerin; N Dmytruk; L Remenieras; J Feuillard; N Gachard
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

5.  MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?

Authors:  Tait D Shanafelt; Neil E Kay; Tim G Call; Clive S Zent; Diane F Jelinek; Betsy LaPlant; William G Morice; Curtis A Hanson
Journal:  Leuk Res       Date:  2008-01-07       Impact factor: 3.156

6.  B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.

Authors:  Tait D Shanafelt; Neil E Kay; Greg Jenkins; Timothy G Call; Clive S Zent; Diane F Jelinek; William G Morice; Justin Boysen; Liam Zakko; Susan Schwager; Susan L Slager; Curtis A Hanson
Journal:  Blood       Date:  2008-11-17       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.